STAT January 14, 2020
Public optimism about American health care seems in short supply if you read the news, which is dominated by coverage of partisan fights over the Affordable Care Act and the continuing crisis of opioid addiction. But innovation in the life sciences sector offers reason to cheer. We’re seeing vital new approaches to research and development driven by the private and philanthropic sectors, focused both on how we finance research and development and how we conduct it.
I’ll start with the finance side of the equation. The center of gravity, as always, is the federal government. Two years ago, Jeffrey Bluestone, Laurie Glimcher, and I argued in STAT that the National Institutes of Health risked losing its edge in biomedical innovation....
Today's Sponsors
Today's Sponsor